A variant of ProMACE-CytaBOM chemotherapy for nonHodgkin’s lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL) Paolo G. Gobbi, Maria L. Ghirardelli, Paolo Avanzini, Luca Baldini, Giovanni Quarta, Caterina Stelitano, Chiara Broglia, Carlo Loni, Vittorio Silingardi, Edoardo Ascari for GISL (Gruppo Italiano...